Analysts See $-0.46 EPS for Fortress Biotech, Inc. (FBIO); DALRADIAN RESOURCES ORDINARY SHARES (DRLDF) Shorts Up By 1.54%

April 17, 2018 - By Lawrence Diaz

Fortress Biotech, Inc. (NASDAQ:FBIO) Logo

Analysts expect Fortress Biotech, Inc. (NASDAQ:FBIO) to report $-0.46 EPS on May, 9.They anticipate $0.16 EPS change or 53.33% from last quarter’s $-0.3 EPS. After having $-0.21 EPS previously, Fortress Biotech, Inc.’s analysts see 119.05% EPS growth. The stock increased 0.23% or $0.01 during the last trading session, reaching $4.36. About 140,344 shares traded. Fortress Biotech, Inc. (NASDAQ:FBIO) has risen 25.00% since April 17, 2017 and is uptrending. It has outperformed by 13.45% the S&P500.

DALRADIAN RESOURCES INC ORDINARY SHARES (OTCMKTS:DRLDF) had an increase of 1.54% in short interest. DRLDF’s SI was 1.90 million shares in April as released by FINRA. Its up 1.54% from 1.87M shares previously. With 70,300 avg volume, 27 days are for DALRADIAN RESOURCES INC ORDINARY SHARES (OTCMKTS:DRLDF)’s short sellers to cover DRLDF’s short positions. The stock 0.20% or $0 during the last trading session, reaching $0.85. It is down 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Fortress Biotech, Inc., a biopharmaceutical company, engages in dermatology product sales, pharmaceutical, and biotechnology businesses in the United States. The company has market cap of $223.85 million. The firm offers CNDO-109, a lysate that activates donor natural killer cells to treat cancer-related and other conditions; tramadol HCl, an intravenous formulation for moderate to moderately severe post-operative pain; CAEL-101 for AL amyloidosis; and CEVA101, which is in Phase II clinical study for severe traumatic brain injury in pediatric patients and adults. It currently has negative earnings. It also provides novel, non-chemotherapy, and immune-enhanced combination treatments for patients with solid tumor cancers; Uracil Topical Cream that is in Phase II to treat and prevent hand-foot syndrome; candidate CUTX-101, a copper histidinate injection for Menkes disease and related copper transport disorders; and novel agents for rare, neglected, or orphan disorders.

Among 3 analysts covering Fortress Biotech (NASDAQ:FBIO), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Fortress Biotech had 10 analyst reports since July 11, 2017 according to SRatingsIntel. As per Tuesday, December 5, the company rating was maintained by H.C. Wainwright. H.C. Wainwright maintained the shares of FBIO in report on Tuesday, January 2 with “Buy” rating. H.C. Wainwright maintained it with “Buy” rating and $1100 target in Thursday, August 10 report. The stock of Fortress Biotech, Inc. (NASDAQ:FBIO) earned “Buy” rating by H.C. Wainwright on Tuesday, July 11. The firm has “Buy” rating given on Tuesday, December 12 by H.C. Wainwright. The company was maintained on Tuesday, March 27 by H.C. Wainwright. The stock of Fortress Biotech, Inc. (NASDAQ:FBIO) earned “Buy” rating by H.C. Wainwright on Friday, March 16. On Wednesday, September 27 the stock rating was maintained by H.C. Wainwright with “Buy”.

Dalradian Resources Inc. engages in the acquisition, exploration, and evaluation of mineral properties. The company has market cap of $293.51 million. It explores for gold and silver ores. It currently has negative earnings. The firm primarily focuses on the development of Curraghinalt gold project in Northern Ireland.

Fortress Biotech, Inc. (NASDAQ:FBIO) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>